Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Fig. 3

Comparison of sSIGLEC-1 with other markers of disease activity. a, b Correlation between the sSIGLEC-1 concentration and the canonical IFN transcriptional signature obtained by NanoString in RNA from same donors. The IFN signature was measured in 24 healthy donors (black) and 34 SLE patients (red) from the discovery cohort (cohort 1) (a), and in 41 SLE patients from the replication cohort (cohort 2) (b). c Correlation between sSIGLEC-1 and IFN-αb2 concentrations measured in plasma samples from 41 SLE patients in cohort 2. d Data depict the correlation between sSIGLEC-1 concentration and the SLE Disease Activity Index (SLEDAI), available from 34 SLE patients from cohort 1. P values were calculated by linear regression. IFN type I interferon, SLE systemic lupus erythematosus, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1

Back to article page